Skip to main content

Advertisement

Table 1 Demographic characteristics of patients

From: Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Characteristics Value
Age (years) (mean ± SD; range) 35.6 ± 11.5 (14–65)
Gender
 Male 19 (76%)
 Female 6 (24%)
Metastases
 None 5 (20%)
 Lymph nodes 13 (52%)
 Skeletal 13 (52%)
 Liver 3 (12%)
 Lungs 3 (12%)
Prior treatment
 Yes 19 (76%)
 No 6 (24%)
Type of prior therapies
 Surgery 14 (56%)
 Chemotherapy 5 (20%)
 Radiotherapy 4 (16%)
131I-MIBG therapy 2 (8%)
 Inoperable/no treatment affected 6 (24%)
Disease status at baseline
 Progressive disease 21 (84%)
 Stable disease 4 (16%)
Anti-hypertensive drugs 14 (56%)
Number of 177Lu-DOTATATE therapy cycles (median, range) 3 (2–8)
Treatment duration
 Median (range) 30 (15–96)
Cumulative activity (GBq) 22.86 ± 9.54 (14.43–50)